- Publicerad
Redeye sees the RPDD and ODD from the FDA as signs that the osteoarthritis programme MIV-711 is moving forward.
Redeye
Redeye sees the RPDD and ODD from the FDA as signs that the osteoarthritis programme MIV-711 is moving forward.
Redeye